Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 11/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.43 |
| ▸ | NCOR1 | O75376 | 1/20 | 0.43 |
| ▸ | DHODH | Q02127 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4183442 | 0.93 | EPHX2 (0.54) | EPHX2HDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL13653266 | 0.92 | EPHX2 (0.46) | EPHX2TRPV1HDAC1HDAC2HDAC3 | |
| SCHEMBL4188365 | 0.91 | TRPV1 (0.48) | EPHX2TRPV1HDAC1HDAC2HDAC3 | |
| SCHEMBL13653281 | 0.91 | HDAC1 (0.48) | EPHX2TRPV1HDAC1HDAC2HDAC3 | |
| SCHEMBL4197918 | 0.91 | HDAC2 (0.49) | TRPV1HDAC1HDAC2HDAC3HDAC4 | |
| SCHEMBL4195363 | 0.91 | HDAC1 (0.52) | EPHX2TRPV1HDAC1HDAC2HDAC3 | |
| SCHEMBL4184370 | 0.88 | HDAC1 (0.43) | EPHX2TRPV1HDAC1HDAC2HDAC3 | |
| SCHEMBL4178941 | 0.87 | HDAC1 (0.49) | EPHX2TRPV1HDAC1HDAC2HDAC3 | |
| SCHEMBL4197887 | 0.87 | HDAC1 (0.49) | EPHX2TRPV1HDAC1HDAC2HDAC3 | |
| SCHEMBL13653271 | 0.87 | ABCB1 (0.47) | EPHX2TRPV1HDAC1HDAC2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247590-A1 | Indane amides | BAYER PHARMACEUTICLAS CORPORATION (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247590-A1 | Indane amides | BAYER PHARMACEUTICLAS CORPORATION (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247590-A1 | Indane amides | BAYER PHARMACEUTICLAS CORPORATION (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247590-A1 | Indane amides | MKI67, PPIP5K2, CCNA1 | EPHX2 3172/4885TRPV1 2361/4885HDAC1 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.